Bringing Research Closer to Patients: How Pragmatic Trial Designs Can Transform Rare Cancer Research
Traditional clinical trials are essential for determining whether new treatments are safe and effective. However, the highly controlled conditions that make these trials rigorous can also make participation difficult. Strict eligibility criteria, frequent hospital visits, additional tests and, often, the need to travel to specialist centres may prevent many patients from taking part. (Adashek and Kurzrock, 2023) These barriers are […]
Exploring Clinical Innovation: A New Blog Series
We are happy to announce a new blog series created in collaboration between the Sarcoma Patient Advocacy Global Network (SPAGN) and the STREXIT 2 Project. In 2026, the series will explore key topics in clinical research, including international collaboration in rare cancer research, the role of Horizon Europe in driving innovation, the integration of real-world […]
Introducing the Clinical Trial leaders of the STREXIT2 Project
Over the last couple of months, we introduced the people and organisations behind the STREXIT2 Project on our social media platforms. In this article, we will focus on the project’s clinical trial leader, Prof. Dr Alessandro Gronchi and the clinical trial co-leader, Dr Winan van Houdt. Dr Alessandro Gronchi, MD, graduated with high honours from […]
Celebrating Sarcoma Awareness Month with the start of EU-funded STREXIT2 project study
On Sarcoma Awareness Month, the European Organisation for Research and Treatment of Cancer (EORTC) and the Syreon Research Institute are delighted to announce the official start of STREXIT2, a complementary observational study of the EORTC 1809 STRASS2 clinical trial focusing on high-risk retroperitoneal sarcoma. STREXIT2 is one of three research projects coordinated by the EORTC, alongside DE-ESCALATE and LEGATO, […]
